vTv Therapeutics, Inc. (NASDAQ: VTVT) Starts Presentation at 29th Annual Roth Conference
vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company that discovers, develops and sells orally administered small molecule drug candidates worldwide. The company’s drug candidate for the treatment of Alzheimer’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end-products, which is in Phase III clinical trials. Its Type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in phase II clinical trials. For more information, visit…